Pharmaceutical chemical and biology researchers need to develop new methods and models to improve the predictivity of preclinical discovery phases and increase the number of good molecules in clinic.   INOVOTION’s unique in vivo technology will allow you to raise the global number of drug candidates tested in clinic without increasing your costs.

INOVOTION performs routine in vivo efficacy evaluation of drug candidates especially for anticancer treatments.

We have developed and validated a technology addressing the major types of cancers concerning the main organs (lung, brain, liver, skin, connective tissues, colon, breast, uterus, pancreas and prostate):

For each assay, we evaluate the in vivo efficacy and toxicity of your candidate compounds on the human tumor, and monitor the main parameters for your anticancer treatments:

• Evolution of human tumor size under treatment to evaluate the potential for tumor regression
• Quantification of nodules to investigate the metastases’ invasion
• Treatment impact on survival rate and induced abnormality

All our assays use human cancer cell lines and reference compounds classically involved in mouse preclinical studies.   Our model is predictive of what happens in mice for all reference molecules, and this has been verified in side-by-side tests.

A standard assay at INOVOTION:

• Is very fast: requires only one month
• Produces results with a high statistical significance (low p.value): includes 15-18 eggs per group
• Requires thousands of times less compound to test its efficacy in comparison with conventional mouse models
• Costs are very competitive

Contact us for further information.